-
On-site negotiations on the adjustment of the national medical insurance drug list involve hundreds of clinical drugs
Time of Update: 2023-02-03
Since the establishment of the National Health Insurance Administration, the list of medical insurance drugs has been adjusted for four consecutive years, and a total of 507 new drugs and good drugs have been included and 391 drugs with uncertain efficacy have been transferred.
-
Far East Cable Innovation Platform was selected as Jiangsu Engineering Research Center
Time of Update: 2022-11-28
(Bian Zongjin) List of Jiangsu Engineering Research Centers in 2020 Jiangsu Engineering Research Center focuses on the national and Jiangsu innovation-driven strategy, deploys an innovation chain around the industrial chain, enhances the unfinalized and competitive industrial chain, and promotes high-quality economic development.
-
Issue 39/2012 - Cobalt is temporarily exempted from REACH authorization
Time of Update: 2022-11-12
(Li Weisong) Cobalt substances are temporarily exempt from REACH authorizationRecently, the European Commission notified the World Trade Organization (WTO) of its proposal to add a part of the substance to the REACH authorized list.
-
In 2021, there are no Chinese pharmaceutical companies in the top ten global generic drug companies. Where is the spring of domestic generic drugs
Time of Update: 2022-08-15
Teva -- sales have fallen for 5 years in a row Teva Pharmaceuticals is a global pharmaceutical company headquartered in Israel and one of the largest generic drug manufacturers in the world.
-
[Lymphoma micro course 2021ASH first look] After IRV, different courses of treatment are followed according to risk stratification. R-HyperCVAD/MTX is used for young newly-treated MCL patients
Time of Update: 2021-12-07
Therefore, they designed the Window 2 study to evaluate the use of IRV in young newly-treated MCL patients after the use of IRV according to risk stratification and sequential different courses of treatment R- HyperCVAD/MTX is used as a consolidation therapy for the safety and efficacy.
-
Statistical Guidelines for Clinical Research of Rare Disease Drugs (Draft for Solicitation of Comments) released
Time of Update: 2021-12-06
On November 18th, CDE drafted the "Guiding Principles for Clinical Research of Rare Disease Drugs (Draft for Comment)", which is now open for comment .
“Guidelines for Statistics of Clinical Research on Rare Disease Drugs (Draft for Comment)” feedback form for soliciting opinions
-
The pharmacy industry has set off a wave of listings, and corporate competition will intensify
Time of Update: 2021-12-01
In August, SpeciHealth, which mainly sells specialty drugs for oncology and other critical diseases, formally submitted a prospectus to the Hong Kong Stock Exchange and plans to list on the main board .
-
NEJM: Sotorasib treatment of KRASp.G12C mutant advanced non-small cell lung cancer Phase II clinical data is gratifying
Time of Update: 2021-06-16
Progression-free survival after Sotorasib treatment, overall survival dataStudies believe that Sotorasib has shown good therapeutic effects and good safety in KRASp. G12C mutant non-small cell lung cancer patients who have previously received platinum chemotherapy or immunotherapy .
-
How to Train Your Dragon: TG6002
Time of Update: 2021-05-02
The design concept of chemotherapeutic drugs like 5-FU is to simply kill tumor cells that replicate faster, but the actual working mechanism is more complicated.
Therefore, in addition to selectively killing tumor cells, oncolytic viruses have a more important purpose for immune activation.
-
The National Health Commission released the second batch of catalogs of encouraged generic drugs containing 17 varieties
Time of Update: 2021-03-25
On March 15th, recently, the National Health Commission, together with the Ministry of Science and Technology, the Ministry of Industry and Information Technology, the National Medical Insurance Admi
-
Dansan extract uproots Helicobacterus
Time of Update: 2021-02-23
Recently, Professor Bi Hongkai of Nanjing Medical University's School of Basic Medicine successfully screened out a new drug candidate for anti-drug-resistant Helicobacter pylbocobacteria - dihydrodansinone I, "dihydrodansinone I in the killing of Helicobacter pylene, not only can destroy the biofilm, but also can kill the bacteria attached to the biofilm, play a role in helicobacter pylene 'rooting up'." ", Bi Hongkai introduced.
-
Mooncake innovation, safety is more important than taste
Time of Update: 2020-09-27
Sales are generally the same, major shopping malls, major supermarkets, all kinds of pie shops and even hotel lobby are full of moon cakes, and now there are more online sales, friends circle "private room mooncakes", sales channels more, purchase is convenient, food safety risks have increased.
-
Take stock of global drug sales in 2019 Top 100
Time of Update: 2020-08-21
drug on the list has sales of more than $10 billion, the first time in history that Keytruda ® is growing at an annual rate of more than 50 percent and is on track to hit Humira ® in the coming years.
-
Scientists find a mechanism that allows cancer cells to 'self-destruct
Time of Update: 2020-08-06
led by Professor Malka Cohen-Armon of the TAU School of Medicine, they found that these proteins can be specifically modified during cell filamentation, releasing an inherent "death mechanism" that eradicates cancer cell self-replication and is validated in a variety of tumor cells, including breast cancer, lung cancer, ovarian cancer, colorectal cancer, pancreatic cancer, blood cancer, brain cancer, and more.
-
34 billion antithrombotic drugs market hit! TOP10 products are out
Time of Update: 2020-07-24
By the impact of collection, "anti-thrombosis one brother" clopidogrel market size has declined And according to the spread of the third batch of collection list, for Grillo, Apixaban in the list, anti-thrombosis drug market further pressure!
